Now Reading: Vaishali Parekh advises caution on Biocon, positive on Sun Pharma
-
01
Vaishali Parekh advises caution on Biocon, positive on Sun Pharma
Vaishali Parekh advises caution on Biocon, positive on Sun Pharma
Market expert Vaishali Parekh of Prabhudas Lilladher has advised caution on Biocon, stating that the stock's momentum has fizzled out previously whenever it was discussed. She said in an interview with Business…
Market expert Vaishali Parekh of Prabhudas Lilladher has advised caution on Biocon, stating that the stock's momentum has fizzled out previously whenever it was discussed. She said in an interview with Business Today that if Biocon reaches the 425-430 rupee zone, it could potentially move to 480 rupees, but she would not rush.
Parekh remains positive on Sun Pharma, saying the stock is doing well and should continue to do so. She also highlighted Glenmark and Laurus Labs, noting strong rallies in both, but clarified that Laurus is not a fresh buy at current levels.
In the cash segment, Parekh pointed to Marksans Pharma, which she said is ready for a breakout, and Morepen Labs. Among healthcare services, she is watching Healthcare Global, Medanta, Rainbow Hospitals, and Apollo Hospitals.
Indian Opinion Analysis
Parekh's call on Biocon reflects a pattern seen with midcap pharma stocks that have struggled to sustain breakouts despite strong fundamentals. The 425-430 rupee resistance zone has been tested before, a clean move past it could signal a shift in sentiment. For Sun Pharma, the largecap leader remains a portfolio staple due to consistent performance. In the hospital space, the buzz around Healthcare Global and Rainbow Hospitals follows a broader rally in healthcare services as occupancy and margins improve. Investors should watch whether Biocon holds above the 425 mark this time to validate the next leg up.
Source: bazaar.businesstoday.in
This brief was synthesised by AI from the source linked above.
